Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4-/- MiceSummary

Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4-/- MiceSummary

Background & Aims: The endocannabinoid system is involved in the modulation of inflammatory, fibrotic, metabolic, and carcinogenesis-associated signaling pathways via cannabinoid receptor (CB)1 and CB2. We hypothesized that the pharmacologic antagonization of CB1 receptor improves cholestasi...

Full description

Bibliographic Details
Main Authors:	Nora Helmrich, Martin Roderfeld, Anne Baier, Anita Windhorst, Diran Herebian, Ertan Mayatepek, Christian Dierkes, Matthias Ocker, Dieter Glebe, Bruno Christ, Yuri Churin, Karuna Irungbam, Elke Roeb
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Cellular and Molecular Gastroenterology and Hepatology
Subjects:	Liver Rimonabant Bile Acid Acute Phase Fibrosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352345X21002630

Similar Items

IL-13 as Target to Reduce Cholestasis and Dysbiosis in <i>Abcb4</i> Knockout Mice
by: Luisa Hahn, et al.
Published: (2020-08-01)

Depression-like phenotype following chronic CB1 receptor antagonism
by: Chad E. Beyer, et al.
Published: (2010-08-01)

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls
by: Carlos Costas-Insua, et al.
Published: (2024-03-01)

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
by: Alison J. Dawson, et al.
Published: (2017-07-01)

INVERSE AGONISTS: MORE THAN JUST ANTAGONISTS?
by: R. N. Alyautdin, et al.
Published: (2022-06-01)

Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory
by: Jiang Lin, et al.
Published: (2024-03-01)

High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain
by: Edward T. Wargent, et al.
Published: (2020-08-01)

Abdominal obesity, cardiometabolic risk and endocannabinoid system
by: G. Bittolo Bon
Published: (2013-05-01)

Potential Implications of Rimonabant on Age-Related Oxidative Stress and Inflammation
by: Renáta Szabó, et al.
Published: (2022-01-01)

Context-dependent effects of the CB1 receptor antagonist rimonabant on morphine-induced behavioral sensitization in female mice
by: Eduardo A. V. Marinho, et al.
Published: (2023-02-01)

Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
by: Marilisa P. Dimmito, et al.
Published: (2019-09-01)

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
by: Fernando Cordido, et al.
Published: (2010-01-01)

Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model
by: Yasmine Amr Issa, et al.

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment
by: Maria Chiara Proto, et al.
Published: (2023-08-01)

Maternal sevoflurane exposure induces neurotoxicity in offspring rats via the CB1R/CDK5/p-tau pathway
by: Yuxiao Wan, et al.
Published: (2023-01-01)

Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs
by: Peter M. Nilsson, et al.
Published: (2010-12-01)

Lipid Storage and Interferon Response Determine the Phenotype of Ground Glass Hepatocytes in Mice and HumansSummary
by: Yuri Churin, et al.
Published: (2021-01-01)

Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling
by: Stefan Almestrand, et al.
Published: (2015-06-01)

The role of cannabinoid receptor 1 in the development of oxidative/nitrosative stress in mice with non-alcoholic fatty liver disease
by: Brkić Dušan, et al.
Published: (2019-01-01)

Reducing Effect of Saikosaponin A, an Active Ingredient of Bupleurum falcatum, on Intake of Highly Palatable Food in a Rat Model of Overeating
by: Paola Maccioni, et al.
Published: (2018-08-01)

Sistema endocanabinoide: modificando los factores de riesgo cardiovascular
by: John Edwin Feliciano Alfonso, et al.
Published: (2006-10-01)

The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
by: José Antonio López-Moreno, et al.
Published: (2007-02-01)

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
by: Adriano Mollica, et al.
Published: (2017-01-01)

Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles
by: Xiaolie He, et al.
Published: (2017-08-01)

Association of ABCB4 and ABCB11 nucleotide variants with intrahepatic cholestasis of pregnancy
by: Milena Gruszczyńska-Losy, et al.
Published: (2019-12-01)

Genomic Methylation Inhibits Expression of Hepatitis B Virus Envelope Protein in Transgenic Mice: A Non-Infectious Mouse Model to Study Silencing of HBV Surface Antigen Genes.
by: Franziska Graumann, et al.
Published: (2015-01-01)

A Complex Case of Cholestasis in a Patient with ABCB4 and ABCB11 Mutations
by: Mariana Ferreira Cardoso, et al.
Published: (2017-11-01)

The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice
by: Francisco J. Bermudez-Silva, et al.
Published: (2016-01-01)

The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells
by: Mansour Haddad
Published: (2021-10-01)

Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
by: Tania Muller, et al.
Published: (2022-03-01)

Modern drugs for obesity and metabolic syndrome treatment (Review)
by: M. L. Maximov, et al.
Published: (2022-12-01)

ABCB4 sequence variation in women with intrahepatic cholestasis of pregnancy
by: Mullenbach, R, et al.
Published: (2003)

Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB<sub>1</sub> Receptor Antagonists after the Fall
by: Taryn Bosquez-Berger, et al.
Published: (2023-08-01)

Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia
by: Luis Santos-Molina, et al.
Published: (2021-08-01)

Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
by: Omar Soler-Cedeno, et al.
Published: (2022-10-01)

What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review
by: R Ara, et al.
Published: (2012-02-01)

ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy.
by: Müllenbach, R, et al.
Published: (2003)

The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice
by: Vincenzo Micale, et al.
Published: (2019-03-01)

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
by: Donatella Fiore, et al.
Published: (2018-01-01)

CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats
by: Li Zhao, et al.
Published: (2021-04-01)